EUVIMEDEUVIMED entdecken
Editorial

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease

Tanya Simuni iD, Christopher S Coffey, Catherine M Kopil, Cora Allen-Savietta, Barbara Wendelberger, Amy Crawford, Ruth B Schneider, Andrew Siderowf, Karl Kieburtz, Caroline M Tanner, Thomas F Tropea, Heidi Whalen und 10 weitere

Annals of Neurology · 2026-10 · 100 (S38)

DOI: 10.1002/ana.78250 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Neurology, online erschienen am 07.05.2026. Verfasst von Tanya Simuni und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Path to Prevention (P2P) platform trial is a multicenter, multi‐regimen, proof of concept, phase 2A, randomized clinical trial evaluating the safety and early efficacy of investigational products for the treatment of early‐stage Neuronal Alpha‐Synuclein disease (NSD) populations. The P2P trial is nested within the Parkinson's Progression Markers Initiative (PPMI), which means that its conceptualization, design, and implementation are based on learnings from the PPMI study. P2P will recruit eligible participants from the PPMI cohort. P2P will also leverage PPMI infrastructure including PPMI study sites and PPMI study cores including the site management, data management, biorepository, imaging, statistical, and data science cores for study execution. This paper reviews the conceptual design of P2P focusing on its relationship with PPMI to demonstrate how the connectivity between PPMI and P2P is essential for the success of the P2P study. P2P is an important step forward in clarifying the clinical trial design and regulatory path for interventions in the early‐stage NSD population. ANN NEUROL 2026;100:S97–S105

Autor:innen und Institutionen

  • Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Biostatistics, University of Iowa, Iowa City, IA.
  • The Michael J. Fox Foundation for Parkinson's Research, New York, NY.
  • Berry Consultants, LLC, Austin, TX.
  • Department of Neurology, University of Rochester, Rochester, NY.
  • Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

ORCID-Profile: Tanya Simuni

Zitieren

APA

Simuni, T., Coffey, C. S., Kopil, C. M., Allen-Savietta, C., Wendelberger, B., Crawford, A., Schneider, R. B., Siderowf, A., Kieburtz, K., Tanner, C. M., Tropea, T. F., Whalen, H., Ramia, L., Kamp, C., Reyes, C., Fabrizio, K., Willson, T., Merriam, E., Kuhl, M. M., …, & Parkinson's Progression Markers Initiative (2026). How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease. Annals of Neurology, 100(S38). https://doi.org/10.1002/ana.78250

Vancouver

Simuni T, Coffey CS, Kopil CM, Allen-Savietta C, Wendelberger B, Crawford A, et al. How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease. Annals of Neurology. 2026;100(S38). doi:10.1002/ana.78250

BibTeX
@article{Simuni2026,
  author = {Simuni, Tanya and Coffey, Christopher S and Kopil, Catherine M and Allen-Savietta, Cora and Wendelberger, Barbara and Crawford, Amy and Schneider, Ruth B and Siderowf, Andrew and Kieburtz, Karl and Tanner, Caroline M and Tropea, Thomas F and Whalen, Heidi and Ramia, Lianne and Kamp, Cornelia and Reyes, Cecilia and Fabrizio, Kimberly and Willson, Tawny and Merriam, Erika and Kuhl, Maggie McGuire and Chowdhury, Sohini and Marek, Kenneth and Parkinson's Progression Markers Initiative, Parkinson's Progression Markers Initiative},
  title = {How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease},
  journal = {Annals of Neurology},
  year = {2026},
  volume = {100},
  number = {S38},
  doi = {10.1002/ana.78250}
}
Kostenlos starten →